Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.

ABSTRACT:

Importance

Aflibercept, 8 mg, may have greater therapeutic benefits compared with aflibercept, 2 mg, in patients with neovascular age-related macular degeneration (nAMD), including potentially improved outcomes and decreased treatment burden.

Objective

To assess safety and efficacy of aflibercept, 8 mg, in patients with nAMD.

Design, setting, and participants

The CANDELA trial was a phase 2, randomized, single-masked, open-label, 44-week clinical trial conducted in the US. Treatment-naive patients with active subfoveal choroidal neovascularization secondary to nAMD and a best-corrected visual acuity score of 78 to 24 letters (approximately 20/32 to 20/320) in the study eye were enrolled between November 2019 and November 2021.

Interventions

Eligible participant

SUBMITTER: Wykoff CC 

PROVIDER: S-EPMC12278850 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature